Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2

NCT00004067 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT00004067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2
Lead sponsor
NSABP Foundation Inc
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2000
Completion date
November 30, 2019
Enrollment
2,130 (actual)
Sites
149

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer